Biomatics Capital Partners

Biomatics Capital Partners investment thesis

Portfolio News Contact Investor Portal Select Page Portfolio We don’t do incremental. We like outliers. The big ideas that shake things up. Created with Snap All ACQUIRED: NEUMORA , PUBLIC ACQUIRED: NEUMORA , PUBLIC ACQUIRED: MSFT , PUBLIC PUBLIC , PUBLIC | CMPX PUBLIC , PUBLIC | NASDAQ:DNLI PUBLIC , PUBLIC | NASDAQ:EDIT ACQUIRED:ILMN , PUBLIC ACQUIRED: BEAM , PUBLIC PUBLIC , PUBLIC | NASDAQ:NMRA ACQUIRED:PACB , PUBLIC ACQUIRED: EXAS , PUBLIC PUBLIC , PUBLIC | NASDAQ:TWST PUBLIC , PUBLIC | NASDAQ:VERV Digital Health Digital Health Medical Technology Gene Editing Proteomics Digital Health CASE STUDY EDITAS MEDICINE From Early-Stage Science to IPO Editas Medicine is harnessing CRISPR-Cas9 gene editing to create genomic medicines for devastating and hard-to-treat diseases, including Usher syn

Biomatics Capital Partners team (2)

Partners and principals at Biomatics Capital Partners:

• Boris Nikolic — sweet spot $5M
• Julie Sunderland — sweet spot $5M

Biomatics Capital Partners portfolio companies

Companies listed on Biomatics Capital Partners's public materials include: Portfolio, News, Investor Portal, All, ACQUIRED: NEUMORA, PUBLIC, ACQUIRED: MSFT, PUBLIC | CMPX, PUBLIC | NASDAQ:DNLI, PUBLIC | NASDAQ:EDIT, ACQUIRED:ILMN, ACQUIRED: BEAM, PUBLIC | NASDAQ:NMRA, ACQUIRED:PACB, ACQUIRED: EXAS, PUBLIC | NASDAQ:TWST, PUBLIC | NASDAQ:VERV, Digital Health, Medical Technology, Gene Editing, Proteomics, CASE STUDY, Negotiatied term sheet valuation, Joined board of directors.

Is Biomatics Capital Partners a fit for your round?

Upload your pitch deck and see whether anyone at Biomatics Capital Partners appears in your top matches.